Big Technologies Poised for Growth Following New Contract Wins and Strategic Partnership

Big Technologies plc (AIM: BIG), a prominent player in electronic monitoring solutions, has announced a series of positive developments, signaling a strong trajectory for 2026. The company's recent trading update highlights new business wins, a strategic partnership, and product certification, all contributing to a confident outlook.

The company has secured new contracts in Lithuania, Latvia, Prince Edward Island (Canada) and Pierce County (Washington state), subject to final contract.

These wins are anticipated to diversify Big Technologies' revenue streams and reduce customer concentration, with the Lithuanian contract alone expected to generate an initial £0.6 million in Annual Recurring Revenue (ARR) in 2026. Furthermore, the Lithuanian contract presents a significant opportunity to grow to a total contract value of approximately €6 million over three years.

Big Technologies has also forged a strategic partnership with US-based Recovery Monitoring Solutions (RMS). This collaboration aims to leverage RMS's 32-year history in delivering innovative solutions by incorporating Buddi's state-of-the-art alcohol monitoring and GPS products. The partnership is expected to expand Buddi's reach within the US market.

The Group has recently developed a new product to measure breath alcohol, called ‘AlcoBreath', which has recently received FCC (Federal Communications Commission) approval in the USA. The unit combines breath alcohol detection, real time GPS tracking, and facial recognition in a robust, compact handheld device. The Group believes there is a significant market, particularly in the USA, for compliance-based alcohol monitoring.

These developments underpin the company's confidence in achieving full-year trading in line with market expectations. Current market forecasts for 2025 revenue range from £48.5 million to £49.5 million, with a consensus of £49.1 million. Adjusted EBITDA is projected to be between £23.7 million and £24.5 million, with a consensus of £24.1 million.

The key drivers for this growth include new contract wins, diversifying revenue, a strategic partnership with RMS expanding US market reach, and product innovation with the FCC approval for the new AlcoBreath product, which opens up a significant market for compliance-based alcohol monitoring.

From the AskTraders perspective, the new contracts and strategic partnership are likely to have a positive impact on investor sentiment. The AlcoBreath product launch could drive further growth, particularly in the US market.

CEO Ian Johnson stated: “We are continuing to progress our transformation programme, strengthening our organisation and delivering profitable growth. We are delighted with the recent awards and validation of the competitiveness of the Buddi proposition to customers globally.”